Literature DB >> 6414363

Comparison of ceftazidime concentrations in bile and serum.

E Bouza, T Hellín, M Rodríguez-Creixems, J Martínez-Beltrán, E Loza, F Baquero.   

Abstract

Biliary excretion of ceftazidime, a new broad-spectrum cephalosporin, was studied in two groups of patients after administration of a 2-g dose intravenously. Group A included 10 patients in whom ceftazidime levels in bile were measured during cholecystectomy. Group B included 10 patients with indwelling biliary tubes in whom ceftazidime levels in bile and serum were simultaneously measured at 0.5, 1, 2, 4, 6, and 8 h after administration of the drug. Although ceftazidime levels were variable, they exceeded the minimal inhibitory concentrations of most biliary tract pathogens in both groups.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6414363      PMCID: PMC185111          DOI: 10.1128/AAC.24.1.104

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  1 in total

1.  Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease.

Authors:  K R Ratzan; C Ruiz; G L Irvin
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

  1 in total
  4 in total

1.  Penetration of cefazolin, ceftriaxone, cefoperazone, and ceftazidime into human gallbladder tissue and bile.

Authors:  S A Berger; Y Levy; A Halevy; A Gorea; R Orda
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

Review 2.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 3.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 4.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.